MedTrace Logo

Procedure RElated Outcomes With the Watchman FLX Left Atrial Appendage Closure Device

NCT03339193 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2017-11-13

No results posted yet for this study

Summary

This study is a single-centre prospective post-market approval of the early experience with the Watchman FLX device for left atrial appendage closure in patients with atrial fibrillation at high risk of thromboembolic stroke and with contraindications to long-term oral antocoagulation therapy.

Conditions

Interventions

DEVICE

Left atrial appendage closure

Percutaneous insertion of a Watchman FLX left atrial appendage closure device under general anesthesia with transesophageal echo guidance.

Sponsors & Collaborators

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Oxford University Hospitals NHS Trust

    lead OTHER

Principal Investigators

  • Tim Betts, MD · Oxford University Hospitals NHS Trust

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03339193 on ClinicalTrials.gov